EP2515912A4 - Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture - Google Patents

Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Info

Publication number
EP2515912A4
EP2515912A4 EP09852472.1A EP09852472A EP2515912A4 EP 2515912 A4 EP2515912 A4 EP 2515912A4 EP 09852472 A EP09852472 A EP 09852472A EP 2515912 A4 EP2515912 A4 EP 2515912A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
vitamin
analogue
cosolvent
surfactant mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09852472.1A
Other languages
German (de)
French (fr)
Other versions
EP2515912A1 (en
Inventor
Karsten Petersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of EP2515912A1 publication Critical patent/EP2515912A1/en
Publication of EP2515912A4 publication Critical patent/EP2515912A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A topical pharmaceutical composition which is an oil-in-water-oil emulsion comprising a vitamin D derivative or analogue dissolved in a mixture of a non-ionic surfactant and a lower alkanol. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis.
EP09852472.1A 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture Withdrawn EP2515912A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/000266 WO2011076206A1 (en) 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Publications (2)

Publication Number Publication Date
EP2515912A1 EP2515912A1 (en) 2012-10-31
EP2515912A4 true EP2515912A4 (en) 2013-12-25

Family

ID=44194970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09852472.1A Withdrawn EP2515912A4 (en) 2009-12-22 2009-12-22 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture

Country Status (13)

Country Link
EP (1) EP2515912A4 (en)
JP (1) JP5548275B2 (en)
CN (1) CN102770143B (en)
AU (1) AU2009357263B2 (en)
BR (1) BR112012015447A2 (en)
CA (1) CA2785249A1 (en)
HK (1) HK1177695A1 (en)
IL (1) IL220513A (en)
MX (1) MX2012007227A (en)
NZ (1) NZ601002A (en)
RU (1) RU2500387C1 (en)
WO (1) WO2011076206A1 (en)
ZA (1) ZA201204619B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107643354B (en) * 2016-07-22 2022-02-01 重庆华邦胜凯制药有限公司 Separation and determination method of calcipotriol starting material A and related impurities
CN106265511A (en) * 2016-08-22 2017-01-04 江苏知原药业有限公司 A kind of calcipotriol betamethasone self-micro emulsion formulation of excellent performance
CN106265485A (en) * 2016-08-22 2017-01-04 江苏知原药业有限公司 A kind of calcipotriol compositions of improved stability
CN106344589B (en) * 2016-11-10 2019-11-26 江苏知原药业有限公司 A kind of Calcipotriol betamethasone composition of improved stability
CN108904445A (en) * 2018-08-06 2018-11-30 江苏知原药业有限公司 Its salts nano suspending liquid
WO2022040773A1 (en) * 2020-08-26 2022-03-03 Canadian Nano Pharmaceutical Technology Inc. Nano-emulsion based compositions, methods for their preparation and their use in delivery of active ingredients
CN115350151B (en) * 2022-09-29 2023-09-12 湖北欣泽霏药业有限公司 High-stability alfacalcidol liquid oral preparation and preparation method thereof
CN116473985A (en) * 2023-03-29 2023-07-25 暨南大学 Polyene antifungal pharmaceutical composition and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition
US20080293681A1 (en) * 2005-11-30 2008-11-27 Galderma S.A. Sprayable pharmaceutical compositions comprising a vitamin d derivative and an oily phase
US20090298801A1 (en) * 2006-11-30 2009-12-03 Galderma S.A. Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39706E1 (en) * 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
JP3340310B2 (en) * 1996-03-28 2002-11-05 株式会社資生堂 Composite emulsion and method for producing the same
EP1051974A4 (en) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd Lotions containing vitamin d 3 derivatives
US6432422B1 (en) * 1997-12-09 2002-08-13 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
DE60006379T2 (en) * 1999-04-23 2004-08-26 Leo Pharma A/S VITAMIN D ANALOGS AND THEIR PHARMACEUTICAL USE
JP2001025359A (en) * 1999-07-15 2001-01-30 Mitsubishi-Kagaku Foods Corp O/w/o type emulsion composition and its production
EP1901709A2 (en) * 2005-06-10 2008-03-26 Galderma S.A. Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
WO2006138056A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
JP4913487B2 (en) * 2006-07-07 2012-04-11 ポーラ化成工業株式会社 Cosmetics characterized by a feeling of use
FR2911781B1 (en) * 2007-01-26 2009-03-20 Fabre Pierre Dermo Cosmetique DERMATOLOGICAL EMULSION AND PREPARATION METHOD
EP1970049A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US20080293681A1 (en) * 2005-11-30 2008-11-27 Galderma S.A. Sprayable pharmaceutical compositions comprising a vitamin d derivative and an oily phase
US20090298801A1 (en) * 2006-11-30 2009-12-03 Galderma S.A. Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents
US20080234239A1 (en) * 2007-03-15 2008-09-25 Derek Wheeler Topical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011076206A1 *

Also Published As

Publication number Publication date
AU2009357263A1 (en) 2012-07-19
RU2500387C1 (en) 2013-12-10
IL220513A0 (en) 2012-08-30
BR112012015447A2 (en) 2016-03-15
NZ601002A (en) 2014-09-26
JP5548275B2 (en) 2014-07-16
JP2013515017A (en) 2013-05-02
CN102770143B (en) 2014-11-05
CA2785249A1 (en) 2011-06-30
IL220513A (en) 2016-05-31
ZA201204619B (en) 2013-09-25
AU2009357263B2 (en) 2015-04-09
CN102770143A (en) 2012-11-07
EP2515912A1 (en) 2012-10-31
MX2012007227A (en) 2012-07-30
WO2011076206A1 (en) 2011-06-30
HK1177695A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
EP2515912A4 (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
EA201290596A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ONE OR MORE ETHERS OF FUMAR ACID IN A DECOMPATED MATRIX
MX352434B (en) Topical formulations having enhanced bioavailability.
ECSP13012618A (en) DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
MX2011011514A (en) Formulations of cannabidiol and methods of using the same.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
CL2007001972A1 (en) ISOPROPILIC ESTER OF THE ACID 4- [6- (6-METHANOSULPHONYL-2-METHYLPIRIDIN-3-ILAMINO) -5-METHYL-PYRIMIDIN-4-ILOXI] PIPERIDIN-1-CARBOXILIC, METABOLISM MODULATORS; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT METABOLIC DISORDERS.
MX2012003555A (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same.
BR112013018352A2 (en) topical minocycline composition and method
EP4306168A3 (en) Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
WO2013093823A3 (en) Topical oil composition for the treatment of fungal infections
IN2014DN07483A (en)
MX2012007229A (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
BR112014020113A8 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD TO DECREASE URINATION FREQUENCY
MY160377A (en) Topical pharmaceutical compositions
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CL2015001502A1 (en) Pharmaceutical composition comprising desloratadine and prendnisolone and use thereof.
MX2015016410A (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
EP3915565A3 (en) Xanthine oxidase inhibitor formulations
ECSP12012332A (en) ASSOCIATION OF INHIBITORS OF XANTINA OXIDASE AND THE INSTATINE AND ITS USE
DOP2015000127A (en) PHARMACEUTICAL FORMULATION OF N- [5- [2- (3,5-DIMETOXIFENIL) ETIL] -2H-PIRAZOL-3-IL] -4 - [(3R, 5S) -3,5-DIMETHYLIPIPERAZIN-1-IL] BENZAMIDA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA

RAX Requested extension states of the european patent have changed

Extension state: BA

Payment date: 20120723

A4 Supplementary search report drawn up and despatched

Effective date: 20131122

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/192 20060101ALI20131118BHEP

Ipc: A61K 9/113 20060101ALI20131118BHEP

Ipc: A61K 9/00 20060101ALI20131118BHEP

Ipc: A61K 31/54 20060101ALI20131118BHEP

Ipc: A61K 31/405 20060101ALI20131118BHEP

Ipc: A61P 17/00 20060101ALI20131118BHEP

Ipc: A61K 31/59 20060101AFI20131118BHEP

17Q First examination report despatched

Effective date: 20170104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170315